# 2026-20460: FDA Yanks 14 Drugs, Spares One After Plea Deal

2026-20460, Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications; Correction, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-06-08; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20460
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20460
- Title: Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications; Correction
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63569
- Published: 2026-10-06
- Effective: 2026-06-08
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

FDA Yanks 14 Drugs, Spares One After Plea Deal

## Summary

The FDA fixed a previous announcement about pulling approvals for 15 generic drug applications. One drug, dimethyl fumarate capsules by Upsher-Smith Labs, will keep its approval because the company asked to keep it. This means 14 drug approvals were withdrawn as planned on June 8, 2026, but Upsher-Smith’s drug stays on the market with no extra costs or delays.

## Abstract

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 7, 2026. The document announced the withdrawal of approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of June 8, 2026. The document indicated that FDA was withdrawing approval of ANDA 210285 for dimethyl fumarate delayed-release capsule, 120 milligrams (mg) and 240 mg, held by Upsher-Smith Laboratories, LLC., U.S. Agent for Sawai USA, Inc., 6701 Evenstad Dr. N, Suite 300, Maple Grove, MN 55369. Before FDA withdrew the approval of this ANDA, Upsher-Smith Laboratories, LLC., U.S. Agent for Sawai USA, Inc., informed FDA that they did not want the approval of the ANDA withdrawn. Because Upsher- Smith Laboratories, LLC., U.S. Agent for Sawai USA, Inc., timely requested that approval of the ANDA not be withdrawn, the approval is still in effect. This notice removes the entry for ANDA 210285.

## Effects PRIA read

- Fourteen generic drug approvals withdrawn: cost, low. The FDA announced that approvals of 15 abbreviated new drug applications (ANDAs) were to be withdrawn, and the withdrawals were effective June 8, 2026. After the correction, one ANDA was preserved, which means approvals for 14 ANDAs were withdrawn as of June 8, 2026.
- Dimethyl fumarate ANDA remains approved: benefit, low. The FDA corrected its May 7, 2026 notice to state that ANDA 210285 for dimethyl fumarate delayed-release capsules, 120 mg and 240 mg, held by Upsher-Smith Laboratories (U.S. Agent for Sawai USA, Inc.), remains approved because the company timely requested that its approval not be withdrawn. The cor…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20460 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20460/teva-pharmaceuticals-usa-inc-et-al-withdrawal-of-approval-of-15-abbreviated-new-drug-applications)
- [2026-20460 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20460.pdf)

## Related
- [Previous: 2026-20459, Agency Information Collection Revision](https://policyrisk.com/federal-register/2026-20459)
- [Next: 2026-20462, Agency Information Collection Activities; Proposed eCollection eComments Reques…](https://policyrisk.com/federal-register/2026-20462)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20460 (as of 2026-10-13).
